GO:0097354 prenylation: Protein Lipidation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097354 prenylation is the covalent attachment of a prenyl group (geranyl, farnesyl, or geranylgeranyl) to a molecule, most commonly a cysteine residue near the C-terminus of a protein.
• Prenylation is essential for membrane anchoring and proper function of small GTPases such as RAS, RHO, RAC, and RAB, which control cell growth, cytoskeleton, and vesicle trafficking.
• Defects in prenylation underlie inherited retinal diseases, renal disease, and cancer, making the pathway a therapeutic target.
• In plants, prenylation mediates stress responses and substrate diversification, with recent insights into enzyme-substrate specificity.
• Prenylation also enhances the biological activity of dietary flavonoids by altering their bioavailability.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are powerful tools to dissect prenylation enzyme function and substrate specificity.
Description
Prenylation (GO:0097354) is a post-translational modification that covalently attaches a prenyl group—either a 15-carbon farnesyl or a 20-carbon geranylgeranyl moiety—to a target molecule, typically a cysteine residue in a C-terminal CaaX motif of a protein. This lipid modification increases hydrophobicity and promotes membrane association, enabling proteins to interact with lipid bilayers and partner proteins. Since its discovery, prenylation has been recognized as a critical regulator of small GTPase function, including RAS, RHO, RAC, and RAB families, which are central to signal transduction, cytoskeletal dynamics, and vesicular transport. The biomedical importance of prenylation is underscored by the clinical development of prenylation inhibitors (e.g., farnesyltransferase inhibitors) for cancer and renal disease, and by inherited disorders such as retinal dystrophies caused by mutations in prenylation enzymes. In plants, prenylation is involved in stress responses and the biosynthesis of prenylated aromatic natural products, with recent studies revealing substrate diversification and enzyme promiscuity. Prenylation also modifies non-protein molecules such as flavonoids, enhancing their biological activity and bioavailability. Thus, understanding prenylation at the molecular, cellular, and organismal levels is essential for both basic biology and translational research.
prenylation At A Glance
| GO ID | GO:0097354 |
|---|---|
| GO term | prenylation |
| Ontology | biological_process |
| Synonym | none |
| Major function | Covalent attachment of a prenyl group (geranyl, farnesyl, or geranylgeranyl) to a molecule, typically a protein cysteine, enabling membrane anchoring and protein interactions. |
| Substrates | Proteins with C-terminal CaaX motifs (e.g., RAS, RHO, RAC, RAB) and small aromatic molecules such as flavonoids. |
| Enzymes | Farnesyltransferase (FTase), geranylgeranyltransferase I (GGTase-I), geranylgeranyltransferase II (GGTase-II/RabGGTase). |
| Reversibility | Generally irreversible; no known dedicated deprenylating enzyme in mammals. |
| Disease relevance | Cancer, inherited retinal diseases, renal disease, and plant stress responses. |
What Is GO:0097354?
Prenylation is the enzymatic covalent attachment of a prenyl group—geranyl, farnesyl, or geranylgeranyl—to a molecule, most often a protein or a small aromatic compound. In proteins, this typically occurs on a cysteine residue within a C-terminal CaaX motif, catalyzed by farnesyltransferase or geranylgeranyltransferase. The reaction is a key post-translational modification that increases lipophilicity and directs proteins to membranes, facilitating protein-protein and protein-lipid interactions.
Why Is prenylation Important in Cell Biology?
Prenylation is a fundamental lipid modification that controls the localization and activity of hundreds of proteins, particularly small GTPases that act as molecular switches in cell proliferation, differentiation, and trafficking. Dysregulation of prenylation is directly linked to oncogenesis (e.g., RAS mutations), inherited retinal degeneration, and renal pathology, making it a validated drug target. In biotechnology, prenylation is exploited for the production of prenylated aromatic natural products with enhanced bioactivity. Moreover, prenylation of dietary flavonoids improves their bioavailability and health-promoting effects. Thus, prenylation research spans cancer biology, neuroscience, plant science, and nutrition.
• Prenylation is required for the membrane targeting and function of RAS, whose mutations drive ~30% of human cancers.
• Inherited mutations in prenylation enzymes (e.g., GGPS1, RABGGTA) cause retinal dystrophies and other developmental defects.
• Farnesyltransferase inhibitors (FTIs) are in clinical trials for renal disease and certain cancers.
• Prenylation regulates neuronal development and synaptic function via small GTPases.
• In plants, prenylation mediates responses to abiotic and biotic stress.
• Prenylated flavonoids exhibit enhanced antioxidant, anti-inflammatory, and anticancer activities.
• Prenylation is essential for the biomanufacturing of prenylated aromatic natural products.
• CRISPR screens targeting prenylation enzymes can identify new therapeutic targets.
• Prenylation defects can be modeled in patient-derived iPSCs for drug discovery.
• Understanding substrate diversification of prenyltransferases enables engineered biosynthesis.
What Happens During prenylation?
Recognition of the CaaX motif
In simple terms: The enzyme first recognizes a specific tag on the protein, called the CaaX box.
Most prenylated proteins contain a C-terminal CaaX motif, where C is cysteine, a is an aliphatic amino acid, and X determines whether the protein is farnesylated or geranylgeranylated. Farnesyltransferase (FTase) prefers X = M, S, Q, or A, while geranylgeranyltransferase I (GGTase-I) prefers X = L or F. This recognition is the first committed step and ensures substrate specificity.
Transfer of the prenyl group
In simple terms: The enzyme attaches a lipid chain to the cysteine, making the protein greasy.
FTase or GGTase-I catalyzes the transfer of a farnesyl or geranylgeranyl group from farnesyl pyrophosphate (FPP) or geranylgeranyl pyrophosphate (GGPP) to the cysteine thiol of the CaaX motif. This covalent attachment increases the protein's hydrophobicity and promotes its association with membranes. For RAB proteins, geranylgeranyltransferase II (RabGGTase) recognizes a different C-terminal motif (CCXX, CXC, or CC) and adds two geranylgeranyl groups.
Membrane anchoring and trafficking
In simple terms: The lipid tail inserts into cell membranes, anchoring the protein where it needs to work.
Following prenylation, the CaaX motif is further processed by RCE1 (protease) and ICMT (methyltransferase), which remove the -aaX tripeptide and methylate the prenylcysteine, respectively. These modifications enhance membrane affinity. Prenylated proteins such as RAS, RHO, and RAB are then targeted to specific membrane compartments (plasma membrane, endosomes, Golgi) where they carry out signaling and trafficking functions.
Regulation of prenylation
In simple terms: Cells control how much prenylation happens by adjusting enzyme levels and substrate availability.
Prenylation is regulated by the availability of FPP and GGPP, which are intermediates in the mevalonate pathway. Statins, which inhibit HMG-CoA reductase, reduce prenyl substrate levels and can indirectly decrease prenylation of small GTPases. Additionally, the expression and activity of prenyltransferases are modulated during development and in disease states, affecting the prenylation status of key signaling proteins.
Prenylation of non-protein molecules
In simple terms: Prenyl groups can also be attached to small molecules like flavonoids, changing their properties.
Prenylation is not limited to proteins; it also modifies aromatic natural products such as flavonoids, coumarins, and alkaloids. Prenyltransferases in plants and fungi catalyze the addition of prenyl groups to aromatic rings, enhancing lipophilicity, bioavailability, and biological activity. This has implications for drug discovery and nutraceutical development.
Key Genes Involved in GO:0097354 prenylation
The following genes encode the core enzymes, substrates, and regulatory proteins involved in prenylation, with representative roles and research relevance.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FNTA | Farnesyltransferase alpha subunit | Essential for FTase and GGTase-I activity; knockout is lethal. |
| FNTB | Farnesyltransferase beta subunit | Catalytic subunit of FTase; target for cancer therapeutics. |
| PGGT1B | Geranylgeranyltransferase I beta subunit | Catalytic subunit of GGTase-I; prenylates RHO and RAC. |
| RABGGTA | Rab geranylgeranyltransferase alpha subunit | Defects cause retinal dystrophy and platelet dysfunction. |
| RABGGTB | Rab geranylgeranyltransferase beta subunit | Required for RAB prenylation and vesicle trafficking. |
| RCE1 | CaaX protease | Removes -aaX after prenylation; knockout affects RAS localization. |
| ICMT | Isoprenylcysteine carboxyl methyltransferase | Methylates prenylcysteine; regulates RAS signaling. |
| RAS (HRAS, KRAS, NRAS) | Small GTPase substrate | Mutations in RAS are common in cancer; prenylation is required for oncogenic activity. |
| RHO (RHOA, RHOB, RHOC) | Small GTPase substrate | Regulates cytoskeleton and cell migration; prenylation inhibitors affect these processes. |
| RAC1 | Small GTPase substrate | Controls lamellipodia and NADPH oxidase; prenylation is essential for membrane targeting. |
| RAB (e.g., RAB1A, RAB5A, RAB7A) | Small GTPase substrates | Regulate vesicle trafficking; prenylation by RabGGTase is required for function. |
| GGPS1 | Geranylgeranyl pyrophosphate synthase | Synthesizes GGPP; mutations cause retinal dystrophy. |
| FDPS | Farnesyl pyrophosphate synthase | Synthesizes FPP and GGPP; target of bisphosphonates. |
| HMGCR | HMG-CoA reductase | Rate-limiting enzyme in mevalonate pathway; statin target. |
| DHDDS | Dehydrodolichyl diphosphate synthase | Involved in dolichol and prenyl synthesis; mutations cause retinitis pigmentosa. |
| PTAR1 | Protein prenyltransferase alpha subunit repeat containing 1 | Regulates geranylgeranylation of RAB proteins. |
| CHM | Rab escort protein 1 (REP1) | Presents RAB proteins to RabGGTase; mutations cause choroideremia. |
How Is prenylation Regulated?
Prenylation is regulated at multiple levels. The availability of the prenyl donors FPP and GGPP is controlled by the mevalonate pathway, which is inhibited by statins. The expression of prenyltransferases (FNTA, FNTB, PGGT1B, RABGGTA, RABGGTB) is modulated during development and in cancer. Additionally, accessory proteins such as Rab escort protein (REP1, encoded by CHM) and Rab GDP dissociation inhibitor (GDI) regulate the presentation and recycling of RAB substrates. Phosphorylation of small GTPases can affect their interaction with prenyltransferases. In plants, prenylation is regulated by stress hormones and developmental cues.
prenylation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RABGGTA | Choroideremia-like retinal dystrophy | Knockout mouse, patient iPSC-derived retinal organoids |
| CHM | Choroideremia | Knockout mouse, AAV-mediated gene therapy |
| KRAS | Pancreatic, lung, and colorectal cancer | Point-mutation knock-in (G12D, G12V) in cell lines and mice |
| GGPS1 | Retinitis pigmentosa, muscular dystrophy | Knockout zebrafish, patient fibroblasts |
| HMGCR | Hypercholesterolemia, renal disease | Overexpression and knockout in hepatocytes and kidney cells |
Cancer
Prenylation is essential for the oncogenic activity of RAS proteins, which are mutated in approximately 30% of human cancers. Farnesyltransferase inhibitors (FTIs) were developed to block RAS prenylation, but clinical efficacy has been limited due to alternative prenylation by GGTase-I. However, FTIs and geranylgeranyltransferase inhibitors (GGTIs) are being explored in combination therapies for leukemia, pancreatic cancer, and other malignancies.
Inherited retinal diseases
Mutations in prenylation enzymes cause inherited retinal dystrophies. For example, mutations in RABGGTA and CHM (REP1) lead to choroideremia, a progressive retinal degeneration. Mutations in GGPS1 and DHDDS cause retinitis pigmentosa and other retinal phenotypes. These disorders highlight the critical role of prenylation in photoreceptor survival and function.
Renal disease
Prenylation inhibitors have shown promise in renal disease models, including diabetic nephropathy and polycystic kidney disease. Statins, which reduce prenyl substrate availability, are used clinically for cardiovascular protection and may also benefit renal function. However, the precise mechanisms remain under investigation.
Neurodegeneration
Prenylation of small GTPases is critical for neuronal development and synaptic plasticity. Defects in prenylation have been implicated in neurodegenerative conditions such as Alzheimer's disease and Parkinson's disease, although direct causal links are still being established.
From prenylation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does knockout of FNTA abolish RAS prenylation? | CRISPR knockout of FNTA in HEK293T or cancer cell lines |
| Does a point mutation in KRAS (G12D) alter sensitivity to FTIs? | Point-mutation knock-in of KRAS G12D in isogenic cell lines |
| Can knock-in of a tagged RAB protein track its prenylation and localization? | Knock-in of GFP-RAB7A in HeLa cells |
| Does overexpression of GGPS1 increase geranylgeranylation? | Overexpression of GGPS1 in retinal pigment epithelial cells |
| Which prenylation enzymes are essential for plant stress response? | CRISPR knockout of plant FTase in Arabidopsis |
| Can CRISPR library screening identify synthetic lethal partners of prenylation inhibitors? | Genome-wide CRISPR knockout library in cancer cells treated with FTIs |
How to Study the prenylation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Metabolic labeling with azido-farnesol | Prenylation of specific proteins | Detecting RAS prenylation in cancer cells |
| Western blot with anti-prenyl antibodies | Levels of prenylated proteins | Assessing FTase inhibitor efficacy |
| Membrane fractionation | Membrane vs. cytosolic localization | Determining prenylation-dependent membrane anchoring |
| Fluorescence microscopy | Subcellular localization of GFP-tagged proteins | Visualizing RAB prenylation and trafficking |
| CRISPR knockout screening | Genes required for prenylation inhibitor sensitivity | Identifying synthetic lethal targets |
| RNA-seq | Transcriptional changes upon prenylation inhibition | Uncovering compensatory pathways |
| Proteomics (IP-MS) | Protein-protein interactions of prenyltransferases | Mapping the prenylation machinery |
| Bioinformatics motif prediction | Candidate prenylated proteins | Genome-wide identification of CaaX proteins |
Metabolic labeling with prenyl precursors
Cells are incubated with radioactive or clickable analogs of FPP or GGPP (e.g., azido-farnesol), followed by click chemistry and detection, to monitor prenylation of target proteins.
Western blotting with prenylation-specific antibodies
Antibodies that recognize prenylated forms of RAS or RHO can be used to assess prenylation status after genetic or pharmacological manipulation.
Membrane fractionation and imaging
Subcellular fractionation separates membrane and cytosolic fractions to determine whether a protein is prenylated and membrane-associated. Fluorescence microscopy of GFP-tagged proteins can visualize localization changes upon prenylation inhibition.
CRISPR screening and bioinformatics
Genome-wide CRISPR knockout or activation screens coupled with prenylation inhibitors can identify genes that modulate sensitivity. Bioinformatics analysis of prenylation motifs (CaaX, CCXX) predicts candidate substrates.
How CRISPR Can Be Used to Study GO:0097354 prenylation
Knockout
CRISPR knockout of prenylation enzymes (e.g., FNTA, FNTB, PGGT1B, RABGGTA) can abolish specific prenylation events, leading to mislocalization of substrate GTPases and revealing their cellular functions. Knockout of RCE1 or ICMT disrupts the CaaX processing pathway, affecting RAS signaling.
Point Mutation
Point mutations in substrate proteins (e.g., KRAS G12D, RHOA F39L) can be introduced to study how specific residues affect prenylation efficiency and inhibitor sensitivity. Point mutations in the CaaX motif (e.g., C186S in RAS) prevent prenylation and serve as negative controls.
Knock-in
Knock-in of tagged versions of prenylated proteins (e.g., GFP-RAB7A, HA-RHOA) allows real-time tracking of localization and trafficking in live cells. Knock-in of disease-associated mutations (e.g., RABGGTA variants) in iPSCs can model retinal dystrophy.
Overexpression
Overexpression of prenyltransferases (e.g., FNTA/FNTB) or substrate proteins (e.g., KRAS) can enhance prenylation and drive oncogenic signaling, providing a platform to test inhibitors. Overexpression of GGPS1 increases GGPP levels and promotes geranylgeranylation.
How EDITGENE Supports prenylation Research
Researchers studying prenylation-related genes often need to determine whether a candidate gene is causally involved in a specific cellular process or disease. CRISPR-based models provide a robust way to manipulate genes with precision, enabling loss-of-function, gain-of-function, and disease-relevant mutation studies. EDITGENE offers a comprehensive suite of services to accelerate prenylation research.
Contact EDITGENE today to design your custom CRISPR model for prenylation research.
Frequently Asked Questions About prenylation
What is prenylation GO:0097354?
Prenylation (GO:0097354) is the covalent attachment of a prenyl group (geranyl, farnesyl, or geranylgeranyl) to a molecule, typically a protein cysteine, enabling membrane anchoring and protein interactions.
What genes are involved in prenylation?
Key genes include FNTA, FNTB, PGGT1B, RABGGTA, RABGGTB, RCE1, ICMT, and substrate GTPases such as RAS, RHO, RAC, and RAB.
What diseases are linked to prenylation defects?
Prenylation defects cause inherited retinal diseases (e.g., choroideremia), renal disease, and contribute to cancer through RAS mutations.
How is prenylation regulated?
Prenylation is regulated by the mevalonate pathway, prenyltransferase expression, and accessory proteins like REP1; statins reduce prenyl substrate availability.
What are the main enzymes in prenylation?
Farnesyltransferase (FTase), geranylgeranyltransferase I (GGTase-I), and geranylgeranyltransferase II (RabGGTase) catalyze prenylation.
Can CRISPR be used to study prenylation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of prenylation enzyme and substrate functions.
What is the role of prenylation in cancer?
Prenylation is required for RAS and RHO GTPase membrane localization and oncogenic signaling; inhibitors are being tested in clinical trials.
How does prenylation affect plant stress responses?
In plants, prenylation of small GTPases and other proteins mediates responses to abiotic and biotic stress.
What methods are used to detect prenylation?
Metabolic labeling with azido-prenyl analogs, western blotting, membrane fractionation, and fluorescence microscopy are common methods.
What is the difference between farnesylation and geranylgeranylation?
Farnesylation adds a 15-carbon farnesyl group, while geranylgeranylation adds a 20-carbon geranylgeranyl group; the CaaX motif X residue determines which enzyme acts.
Conclusion
Prenylation (GO:0097354) is a fundamental lipid modification that controls the localization and function of hundreds of proteins, particularly small GTPases. Its roles in cancer, inherited retinal diseases, renal disease, and plant stress responses make it a high-priority research area. CRISPR-based models, combined with biochemical and imaging methods, provide powerful tools to dissect prenylation mechanisms and identify therapeutic targets. EDITGENE offers comprehensive services to support these studies, from knockout and knock-in cell lines to library screening and bioinformatics.
References
- 1. Hála M et al.. 2019. Protein Prenylation in Plant Stress Responses.. Molecules 24(21) PMID: 31671559
- 2. An T et al.. 2023. Prenylation: A Critical Step for Biomanufacturing of Prenylated Aromatic Natural Products.. J Agric Food Chem 71(5):2211-2233 PMID: 36716399
- 3. Cox AD et al.. 1992. Protein prenylation: more than just glue?. Curr Opin Cell Biol 4(6):1008-16 PMID: 1485954
- 4. Chevalier Q et al.. 2025. Protein Prenylation Makeovers in Plants: Insights into Substrate Diversification.. Int J Mol Sci 26(21) PMID: 41226669
- 5. Roosing S et al.. 2014. Prenylation defects in inherited retinal diseases.. J Med Genet 51(3):143-51 PMID: 24401286
- 6. Reddy JM et al.. 2020. Regulation of Small GTPase Prenylation in the Nervous System.. Mol Neurobiol 57(5):2220-2231 PMID: 31989383
- 7. Khwaja A et al.. 2000. Prenylation inhibitors in renal disease.. Lancet 355(9205):741-4 PMID: 10703816
- 8. Mukai R. 2018. Prenylation enhances the biological activity of dietary flavonoids by altering their bioavailability.. Biosci Biotechnol Biochem 82(2):207-215 PMID: 29307271
